drugset / Trial / NCT06696742

PD1 Inhibitors Combined With Clostridium Butyricum for Urothelial Carcinoma

NCT06696742

RandomizedParallel-groupDouble-blindTreatment

Summary

This study intends to explore whether the combination of Clostridium butyricum can improve the current situation of poor anti-PD1 treatment effect in patients with bladder cancer.

Timeline

Start
2024-02-01
Primary completion
2029-02-01
Completion
2029-02-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Clostridium butyricum Other / unclassified 20 mg
Comparator Cisplatin Other / unclassified 70 mg/m2
Background Gemcitabine Small molecule 1 g